Angiotensin-converting enzyme insertion/deletion polymorphism modulates coronary release of tissue plasminogen activator in response to bradykinin

Hypertension Research

Volumn 27, Issue 1, 2004, Pages 39-45

  Ohira, Naoto ^a   Matsumoto, Tetsuya ^a   Tamaki, Shinji ^a   Takashima, Hiroyuki ^a   Tarutani, Yasuhiro ^a   Yamane, Tetsunobu ^a   Yasuda, Yo ^a   Horie, Minoru ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Angiotensin converting enzyme; Bradykinin; DD genotype; Tissue plasminogen activator

Indexed keywords

ACETYLCHOLINE; ALDOSTERONE; ANGIOTENSIN; ANTIGEN; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; RENIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AORTA; ARTICLE; BLOOD FLOW VELOCITY; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY CONSTRICTION; CORONARY ARTERY DILATATION; CORONARY SINUS; CORRELATION ANALYSIS; DOPPLER FLOWMETER; ENZYME ACTIVITY; ENZYME RELEASE; FEMALE; FIBRINOLYSIS; GENE DELETION; GENE INSERTION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENOTYPE; HEART CATHETERIZATION; HEART INFARCTION; HEMATOCRIT; HUMAN; LEFT CORONARY ARTERY; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MICROVASCULATURE; POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; VASCULAR ENDOTHELIUM;

AGED; BRADYKININ; CARDIOMYOPATHIES; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; CORONARY VESSELS; FEMALE; FIBRINOLYSIS; GENE DELETION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; TISSUE PLASMINOGEN ACTIVATOR;

EID: 1042309474     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.27.39     Document Type: Article

References (29)

1. Villard E, Soubrier F: Molecular biology and genetics of the angiotensin-1-converting enzyme: potential implications in cardiovascular diseases. Cardiovasc Res 1996; 32: 999-1007.
2. Cambien F, Poirier O, Lecerf L, et al: Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-644.
3. Agerholom-Larsen B, Nordestgaard BG, Steffensen R, Sorensen TIA, Jensen G, Tybjarg-Hansen A: ACE gene polymorphism: ischemic heart disease and longevity in 10150 individuals. Circulation 1997; 95: 2358-2367.
4. Danser AHJ, Schalekamp MADH, Bax WA, et al: Angiotensin-converting enzyme in the human heart. Circulation 1995; 92: 1387-1388.
5. Prasad A, Narayanan S, Husain S, et al: Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition. Circulation 2000; 102: 35-41.
6. Arcaro G, Solini A, Monauni T, et al: ACE genotype and endothelium-dependent vasodilation of conduit arteries and forearm microcirculation in humans. Arterioscler Thromb Vasc Biol 2001; 21: 1313-1319.
7. van den Eijnden-Schrauwen Y, Kooistra T, de Vries RE, Emeis JJ: Studies on the acute release of tissue-type plasminogen activator from human endothelial cells in vitro and in rats in vivo: evidence for a dynamic storage pool. Blood 1995; 85: 3510-3517.
8. Minai K, Matsumoto T, Horie H, et al: Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2001; 37: 1565-1570.
9. The SOLVED Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
10. Pfeffer MA, Braunwald E, Moye LA, et al: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669-677.
11. Matsumoto T, Minai K, Horie H, et al: Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. J Am Coll Cardiol 2003; 41: 1373-1379.
12. Iwai N, Ohmichi N, Nakamura Y, Kinoshita M: The DD genotype of the angiotensin-converting enzyme gene is a risk factor for left ventricular hypertrophy. Circulation 1994; 90: 2622-2628.
13. Tamaki S, Nakamura Y, Tsujita Y, et al: Polymorphism the angiotensin converting gene and blood pressure in a Japanese general population (the Shigaraki Study). Hypertens Res 2002; 25: 843-848.
14. Katsuya T, Iwashita Y, Sugimoto K, et al: Effects of antihypertensive drugs and gene variants in the renin-angiotensin system. Hypertens Res 2001; 24: 463-467.
15. Kawamoto R, Kohara K, Tabara Y, Miki T: An interaction between systolic blood pressure and angiotensin-converting enzyme gene polymorphism on carotid atherosclerosis. Hypertens Res 2002; 25: 875-880.
16. Ludwig E, Corneli PS, Anderson JL, Marshall HW, Lalouel J-M, Ward RH: Angiotensin-converting enzyme gene polymorphism is associated with myocardial infarction but not with development of coronary stenosis. Circulation 1995; 91: 2120-2124.
17. Iwai N, Tamaki S, Ohmichi N, Kinoshita M: The II genotype of the angiotensin-converting enzyme gene delays the onset of acute coronary syndromes. Arterioscler Thromb Vasc Biol 1997; 17: 1730-1733.
18. Mancini GBJ, Henry GC, Macaya C, et al: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996; 94: 258-265.
19. Groves P, Kurz S, Just H, Drexler H: Role of endogenous bradykinin in human coronary vasomotor control. Circulation 1995; 92: 3424-3430.
20. Takahashi N, Hagaman JR, Kim H, Smithies O: Computer simulations of blood pressure regulation by the renin-angiotensin system. Endocrinology 2003; 144: 2184-2190.
21. Murphey LJ, Gainer JV, Vaughan DE, Brown NJ: Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. Circulation 2000; 102: 829-832.
22. Newby DE, Wright RA, Dawson P, et al: The L-arginine/nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man. Cardiovasc Res 38; 1998: 485-492.
23. Brown NJ, Gainer JV, Murphey LJ, Vaughan DE: Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B2 receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation 2000; 102: 2190-2196.
24. Prasad A, Husain S, Schenke W, Mincemoyer R, Epstein N, Quyyumi AA: Contribution of bradykinin receptor dysfunction to abnormal coronary vasomotion in humans. J Am Coll Cardiol 2000; 36: 1467-1473.
25. Butler R, Morris AD, Burchell B, Struthers AD: DD angiotensin-converting enzyme gene polymorphism is associated with endothelial dysfunction in normal humans. Hypertension 1999; 33: 1164-1168.
26. Prasad A, Narayanan S, Waclawiw MA, Epstein N, Quyymi AA: The insertion/deletion polymorphism of the angiotensin-converting enzyme gene determines coronary vascular tone and nitric oxide activity. J Am Coll Cardiol 2000; 36: 1579-1586.
27. Kim D-K, Kim J-W, Kim S, et al: Polymorphism of angiotensin converting enzyme gene is associated with circulating levels of plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 1997; 17: 3242-3247.
28. Margaglione M, Grandone E, Vecchione G, et al: Plasminogen activator inhibitor-1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward: relation to polymorphism of PAI-1 and angiotensin converting enzyme (ACE) genes. Arterioscler Thromb Vasc Biol 1997; 17: 2082-2087.
29. Thogersen AM, Jansson JH, Boman K, et al: High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women. Circulation 1998; 98: 2241-2247.